Latest & greatest articles for schizophrenia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on schizophrenia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on schizophrenia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for schizophrenia

81. Alpha-7 nicotinic agonist improves cognition in schizophrenia

Alpha-7 nicotinic agonist improves cognition in schizophrenia Alpha-7 nicotinic agonist improves cognition in schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password (...) For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Alpha-7 nicotinic agonist improves cognition in schizophrenia Article Text Pharmacological interventions Alpha-7 nicotinic agonist improves cognition in schizophrenia Stephen R. Marder Statistics from Altmetric.com No Altmetric data available for this article. ABSTRACT FROM: Keefe RS, Meltzer HA, Dgetluck N, et al . Randomized, double-blind, placebo-controlled study of encenicline

Evidence-Based Mental Health2016

82. Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders

Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia and mood disorders Article Text Causes and risk factors Impact of additive alcohol and substance use disorders on the mortality of people with schizophrenia

Evidence-Based Mental Health2016

83. Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia?

Pharmacological interventions: Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user (...) name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Is long-acting injectable aripiprazole useful for the treatment of acute exacerbation of schizophrenia? Article Text Further commentaries Electronic pages Pharmacological interventions Is long-acting injectable aripiprazole useful for the treatment of acute

Evidence-Based Mental Health2016

86. [Group psychoeducational intervention in relatives of patients suffering from schizophrenia].

[Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. 26709990 2015 12 29 2016 12 13 2016 12 30 1105-2333 25 4 2015 Oct-Dec Psychiatrike = Psychiatriki Psychiatriki [Group psychoeducational intervention in relatives of patients suffering from schizophrenia]. 243-54 The present research paper aims at assessing the effectiveness of a psychoeducational intervention in relatives' groups of patients with schizophrenia or schizoaffective disorder. It examines (...) Educational Measurement Family psychology Family Therapy Female Health Education methods Humans Male Outcome Assessment (Health Care) Problem Solving Schizophrenic Psychology 2015 12 29 6 0 2015 12 29 6 0 2016 12 15 6 0 ppublish 26709990

Psychiatrike = Psychiatriki2015

87. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review | CADTH.ca Find the information you need Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Published on: August 23, 2012 (...) Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from [CADTH Optimal Use Report; Volume 1, Issue 1B]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Schizophrenia is a mental illness that requires lifelong treatment 1 and is associated with symptoms that include hallucinations, delusions, cognitive impairment, disorganized thoughts, social withdrawal, and low motivation. 2

CADTH - Health Technology Assessment2015

88. Cognitive behavioural therapy (brief versus standard duration) for schizophrenia.

Cognitive behavioural therapy (brief versus standard duration) for schizophrenia. BACKGROUND: Cognitive behavioural therapy for people with schizophrenia is a psychotherapeutic approach that establishes links between thoughts, emotions and behaviours and challenges dysfunctional thoughts. There is some evidence to suggest that cognitive behavioural therapy for people with psychosis (CBTp) might be an effective treatment for people with schizophrenia. There are however, limitations in its (...) provision due to available resource and training issues. One way to tackle this issue might be to offer a brief version of CBTp. OBJECTIVES: To review the effects of brief CBTp (6 to 10 regular sessions given in less than 4 months and using a manual) for people with schizophrenia compared with standard CBTp (12 to 20 regular sessions given in 4 to 6 months and using a manual). SEARCH METHODS: We searched the Cochrane Schizophrenia Group's Trials Register (August 21, 2013 and August 26, 2015) which

Cochrane2015

89. Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses

Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses | CADTH.ca Find the information you need Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Atypical Antipsychotics for Schizophrenia: Combination Therapy and High Doses Published on: December 15, 2011 Project Number: HO503 Product Line: Result type: Report The Canadian Agency for Drugs and Technologies in Health (...) (CADTH) has undertaken an optimal use project to assess the clinical and economic impact of using atypical antipsychotic combination therapy, as well as high-dosing treatment strategies, in adolescents and adults with schizophrenia. The current project has several key components: Appraise the clinical and cost-effectiveness of combination and high-dose therapy with atypical antipsychotic agents for the treatment of schizophrenia Develop optimal use recommendations or advice Identify gaps in current

CADTH - Optimal Use2015

90. Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis.

Voxel-based morphometry for separation of schizophrenia from other types of psychosis in first episode psychosis. BACKGROUND: Schizophrenia is a psychiatric disorder which involves distortions in thought and perception, blunted affect, and behavioural disturbances. The longer psychosis goes unnoticed and untreated, the more severe the repercussions for relapse and recovery. There is some evidence that early intervention services can help, and diagnostic techniques that could contribute to early (...) an individual will progress on to developing schizophrenia as opposed to other types of psychosis. OBJECTIVES: To determine whether VBM applied to the brain can be used to differentiate schizophrenia from other types of psychosis in participants who have received a clinical diagnosis of first episode psychosis. SEARCH METHODS: In December 2013, we updated a previous search (May 2012) of MEDLINE, EMBASE, and PsycInfo using OvidSP. SELECTION CRITERIA: We included retrospective and prospective studies

Cochrane2015

91. Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review

Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review | CADTH.ca Find the information you need Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Combination and High-Dose Atypical Antipsychotic Therapy in Patients with Schizophrenia: Systematic Review Published on: August 23, 2012 (...) Product Line: , CADTH Technology Overviews Issue: Volume 2, Issue 3 Result type: Report Adapted from [CADTH Optimal Use Report; Volume 1, Issue 1B]. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2011. For more information on this project, visit Introduction Schizophrenia is a mental illness that requires lifelong treatment 1 and is associated with symptoms that include hallucinations, delusions, cognitive impairment, disorganized thoughts, social withdrawal, and low motivation. 2

CADTH - Health Technology Assessment2015

92. What is the effect of maintenance treatment with antipsychotica for people with schizophrenia?

What is the effect of maintenance treatment with antipsychotica for people with schizophrenia? What is the effect of maintenance treatment with antipsychotica for people with schizophrenia? - Nasjonalt kunnskapssenter for helsetjenesten Main menu Menu The Knowledge Centre for the Health Services is part of the Norwegian Institute of Public Health since January 1, 2016. For new publications, please go to Search Notat What is the effect of maintenance treatment with antipsychotica for people (...) with schizophrenia? Published 13/05/2015 Dalsbø TK, Dahm KT, Reinar LM. What is the effect of maintenance treatment with antipsychotica for people with schizophrenia?. Notat – 2015. ISBN 978-82-8121-958-8 Key messages Plain language summary from the included Cochrane systematic review: “ Maintenance treatment with antipsychotic drugs for schizophrenia Antipsychotic drugs are the mainstay of treatment of schizophrenia. The current report presents the first systematic review comparing the effects of all

The Norwegian Knowledge Centre for the Health Services2015

93. Lurasidone (Latuda) - schizophrenia

Lurasidone (Latuda) - schizophrenia %PDF-1.5 %���� 91 0 obj > endobj 102 0 obj >/Filter/FlateDecode/ID[ ]/Index[91 27]/Info 90 0 R/Length 67/Prev 195570/Root 92 0 R/Size 118/Type/XRef/W[1 2 1]>>stream h�bbd``b`*�S@��`�\@D$HV H0���AJt�ĵ/ L� �@ ���?�k endstream endobj startxref 0 %%EOF 117 0 obj >stream h�b``�d``�e�3�F fa�h@�b�!��� ��8L����0�]����z�b�,�f���QFm�Ǔ � endstream endobj 92 0 obj >/Metadata 2 0 R/PageLayout/OneColumn/Pages 89 0 R/StructTreeRoot 6 0 R/Type/Catalog>> endobj 93 0 obj

All Wales Medicines Strategy Group2015

94. Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction

Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone and olanzapine dose reduction | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your (...) username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Improving symptoms and side effects in older patients with schizophrenia with decreasing dopamine D2/3 receptor occupancy following risperidone

Evidence-Based Mental Health2015

95. Psychosis and schizophrenia

Psychosis and schizophrenia Psychosis and schizophrenia - NICE CKS Clinical Knowledge Summaries Share Psychosis and schizophrenia - Summary Psychosis is a disordered mental state characterized principally by positive symptoms such as hallucinations, delusions, and thought disorder. Psychotic symptoms are cardinal features of psychotic disorders such as schizophrenia, but may be caused by medicines and substance misuse, and by medical conditions such as sepsis in the elderly. Psychotic disorders (...) , including schizophrenia, are conditions in which psychosis occurs for a significant period of time. They may also be associated with negative symptoms (for example emotional blunting, reduced speech, loss of motivation, self neglect, and social withdrawal). With treatment, psychotic symptoms may resolve fully, recur intermittently with periods of remission between, or persist. Complications include: An increased risk of premature death due to an increased risk of suicide, cardiovascular disease

NICE Clinical Knowledge Summaries2015

96. Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults

Vraylar (cariprazine) - To treat schizophrenia and bipolar disorder in adults Vraylar (Cariprazine) U.S. Department of Health and Human Services Search FDA Submit search Vraylar (Cariprazine) Vraylar (Cariprazine) Company: Forest Laboratories, LLC Application No.: 204370 Orig1 and Orig2 Approval Date: September 17, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2015

97. Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia

Aristada (aripiprazole lauroxil) - To treat adults with schizophrenia Aristada (aripiprazole lauroxil) U.S. Department of Health and Human Services Search FDA Submit search Aristada (aripiprazole lauroxil) Aristada (aripiprazole lauroxil) Company: Alkermes, Inc. Application No.: 207533 Approval Date: October 5, 2015 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) (PDF

FDA - Drug Approval Package2015

98. Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes

Cohort study: Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes | Evidence-Based Nursing This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous thromboembolism and adverse neonatal outcomes Article Text Midwifery Cohort study Pregnant women with schizophrenia are at higher risk of pre-eclampsia, venous

Evidence-Based Nursing (Requires free registration)2015

99. Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia

Causes and risk factors: Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username (...) * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Elevated C reactive protein in adults predicts the later development of late-onset or very-late-onset schizophrenia Article Text Electronic pages Causes and risk factors Elevated C reactive protein in adults predicts the later development of late

Evidence-Based Mental Health2015

100. Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia

Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Article Text Psychological interventions Sustained antipsychotic effect and delayed self-esteem improvement of metacognitive training for schizophrenia Jerome Favrod 1

Evidence-Based Mental Health2015